UA139008U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

A method for predicting the development of osteoarthritis, including clinical examination, radiography, and additionally determine in the patient's serum polymorphism of nitric oxide synthase gene (eNOS T786C), the content of osteocalcin, transforming growth factor beta 1 (TGF-bryogo), , oxyproline and with a homozygous carrier of 786-CC, levels of osteocalcin <21 ng / ml, TGF-b1 <14 ng / ml, COMP> 595 ng / ml, oxyproline> 15 μmol / l predict the development of osteoarthritis.

Description

The proposed useful model, namely the method of predicting the development of osteoarthritis, belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in the diagnosis of the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include radiography, examination of a biopsy of the synovial membrane, synovial fluid, a biopsy of cartilage (Okorokov

A.N. Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of an opportunity to predict the dynamics of the process in the early subclinical stages, to prevent its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis at an early stage.

According to the useful model, in addition to clinical examination and radiography, the polymorphism of the nitric oxide synthase gene (emMmoOo5 T1786С), the content of osteocalcin, transforming growth factor beta 1 (TGF-DV1), cartilage oligomeric matrix protein (COMP), oxyproline and with homozygous carrier 786-SS, levels of osteocalcin "21 ng/ml, TFR-D1 "14 ng/ml, SOMR "595 ng/ml, oxyproline 215 μmol/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, x-rays are taken, the emoz T786C gene polymorphism is determined, the content of osteocalcin is determined by the enzyme immunoassay method,

TFR-D1, COMP, oxyproline. With homozygous carrier 786-SS and levels of osteocalcin "21 ng/ml, TFR-DI "14 ng/ml, SOMR "595 ng/ml, oxyproline 215 μmol/l predict the development of osteoarthritis.

A specific example of using the method

Hospitalized O., 68 years old, was admitted to the clinic due to pain syndrome in the right hip joint. Examined, x-ray taken. No signs of osteoarthritis were found. The emo5 T786C gene polymorphism and the content of osteocalcin, TFR-D1Y, SOMP, and oxyproline were determined in the serum. A homozygous carrier of 786-SS was established, the levels of osteocalcin - 17 ng/ml, TFR-DI - 7.8 ng/ml, COMP - 755 ng/ml, oxyproline 29 μmol/l. The development of osteoarthritis was diagnosed. After 12 months on

X-rays revealed the phenomena of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that the polymorphism of the nitric oxide synthase gene (6МО5 17860), the content of osteocalcin, transforming growth factor beta 1 (TGF-DV1), cartilage oligomeric matrix protein (COMP), oxyproline and with homozygous carrier 786-SS, levels of osteocalcin "21 ng/ml, TFR-DI "14 ng/ml, COMP "595 ng/ml, oxyproline 215 μmol/l predict the development of osteoarthritis.